Carvedilol activates nuclear factor E2-related factor 2/ antioxidant response element pathway to inhibit oxidative stress and apoptosis of retinal pigment epithelial cells induced by high glucose

Yu Zhang, Mingcun Li, Weixing Wang, and Siyu He

Department of Ophthalmology, Nantong Haimen People’s Hospital, Nantong, Jiangsu Province, China

ABSTRACT

Diabetic retinopathy (DR) is the most prominent manifestation of diabetic microangiopathy and is a serious complication of diabetes. Despite extensive research focusing on DR, treatment options for DR are still limited. Carvedilol (CAR) has vasodilatory, antioxidant stress and anti-inflammatory effects and poses a vital role in addressing the issue of diabetic complications. This paper attempts to explore this property of CAR and investigate into its effects on DR. First, ARPE-19 cells were treated with different concentrations of CAR and cells were induced with 30 mM high glucose (HG) to establish a DR cell model. Cell viability was assayed by cell counting kit-8 (CCK-8) with or without HG induction. Cellular inflammation and oxidative stress were evaluated by enzyme-linked immunosorbent assay (ELISA) and corresponding kits. The measurement of apoptosis levels was conducted by Terminal dUTP nick-end labeling (TUNEL) and Western blotting. The protein levels related to Nrf2/ARE signaling pathway were assessed by Western blotting. Finally, cellular inflammation, oxidative stress and apoptosis in ARPE-19 cells pretreated with Nrf2 inhibitor ML385 were tested again by the same methods. Results showed that under HG induction, CAR effectively improved ARPE-19 cell viability, inhibited cellular inflammation, oxidative stress, and apoptosis. Moreover, CAR activated Nrf2/ARE signaling pathway, which further suppressed cellular inflammation, oxidative stress, and apoptosis. Overall, CAR inhibited HG-induced oxidative stress and apoptosis in retinal pigment epithelial cells by activating Nrf2/ARE pathway.

Introduction

Diabetic retinopathy (DR) is the most important manifestation of diabetic microangiopathy and is one of the serious complications of diabetes mellitus, which can lead to retinal damage and vision loss [1]. Early symptoms of DR include microaneurysms, spot and blot hemorrhages, cotton wool spots and intraretinal microvascular abnormalities [2]. The currently dominant treatment approach for DR is the control of microvascular complications, including intravitreal drug therapy, laser photocoagulation and vitreous surgery [3]. These treatment methods, however, are only effective for advanced DR where vision has been severely affected, prospective strategies are still deficient in the early diagnosis and prevention of DR. As the prevalence of diabetes increases, the number of patients diagnosed with DR has dramatically enlarged, and the treatment costs have been also raised [4]. With special attention to the early stages of diabetes, there is a growing recognition that complex neuronal, glial and microvascular abnormalities progressively disrupt retinal function [5]. To avoid making DR one of the major burdens on public health and to reduce the associated costs, it is extremely crucial to look for new and more effective strategies to prevent and treat DR.

Oxidative stress and inflammation are key points in the pathogenesis of retinopathy [6]. In addition, excessive blood sugar gives rise to the deposition of atherosclerotic plates, which in turn provokes inflammation of the retinal vessels [7]. Carvedilol (CAR), a blocking agent of adrenergic receptors, has been broadly used for the treatment of cardiovascular disorders [8]. It has been well documented that CAR has anti-angiogenic [9], anti-oxidative stress and anti-inflammatory effects [8]. An example is that CAR prevents pancreatic β
cell damage and type 1 diabetes (T1D) development in mice by inhibiting inflammatory mediators and oxidative mediators [10]. Another case is that CAR reduces paraquat-induced lung damage by suppressing inflammation and oxidative stress [11]. On the other hand, due to its antioxidant capacity, CAR also has a significant impact on neuroprotection. An example carried out by Liu Bei [12] is that CAR potently protected against retinal degeneration and inhibited both optic nerve injury (ONI)-induced nitric oxide synthase expression in the retina and activation of the apoptosis signal-regulated kinase 1 (ASK1) and p38 mitogen-activated protein kinase (MAPK) pathways, all of which suggested that CAR had neuroprotective and neuroregenerative effects.

Additionally, nuclear factor E2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway is effective against oxidative stress and neuroinflammation in neurodegenerative diseases [13]. Nrf2/ARE signaling pathway was also activated by Parkin overexpression to reduce inflammatory mediated cardiomyocyte apoptosis [14]. It was reported that CAR may be protective against 6-OHDA-induced neurotoxicity in PC12 cells by the activation of Akt and Nrf2/ARE signaling pathways [15].

As a consequence, we put forward the hypothesis that CAR can activate the Nrf2/ARE pathway to play a protective role in DR. The purposes of our research were to explore the effect of CAR on oxidative stress and apoptotic damage in HG-induced retinal pigment epithelial cells, and analyze the regulation of CAR on Nrf2/ARE pathway. This study may provide a new insight into the treatment of DR.

Materials and Methods

Cell culture and treatment

The human retinal pigment epithelial cell lines ARPE-19 were got from American Type Culture Collection (Manassas, VA, USA). The cell culture dishes required here were Dulbecco’s modified Eagle’s medium/nutrient mixture F12 (Procell, Wuhan, China) with 10% fetal bovine serum (Rwdls, Shenzhen, China) and 100 U/mL penicillin/streptomycin. These mediums were placed in a suitable incubator with 95% air and 5% CO₂ at 37°C. For the experiments, some of the dishes were added with 30 mM high glucose (HG) for 9 days incubation to establish DR cell model [16]. Different concentrations of CAR were added to the established cell model for subsequent experimental studies. The other part was handled only by CAR at the doses of 2.5, 5, 10, 20 μM [15,17] for 2 h. CAR was supplied by Qilu Pharmaceutical (Jinan, China). Cells were pretreated with 10 μmol/L Nrf2 inhibitor ML385 (MedChemExpress, Shanghai, China) for 24 h and stored for the later experiments.

CCK-8 assay

CCK-8 kit (Engreen, Beijing, China) was in detection of cell viability in line with the recommendations of vendor. Cell suspension cultivation was carried out in 96-well plates at 37°C in a 5% CO₂ atmosphere. Then, 10 μL CCK-8 solution was added into each well for 4 h. Finally, it was tested with a microplate reader (Reagen, Shenzhen, China) when the absorbance was at 450 nm [18].

ELISA detection

ARPE-19 cells (1 × 10⁵) were plated into 96-well plates and processed according to experimental needs. Then, cell supernatant was collected and the levels of inflammatory cytokines tumor necrosis factor (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) in ARPE-19 cells were assessed by means of ELISA kits (Elabscience, Wuhan, China) conformed with the guidelines of manufacturer. Briefly, capture antibodies were diluted and a 96 well-plate was coated with 100 μL diluted antibodies and incubated over-night at 4°C, rinsed and blocked with blocking buffer at room temperature for 1 h. Samples and standards were then incubated in the plate for 2 h at room temperature. Plates were then rinsed three times and incubated with substrate solution. Reaction was stopped by adding stop solution to each well. Optical density was determined under a plate reader at 450 nm [19].

The measurement of malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-PX)

The activities of malondialdehyde (MDA) were detected with the aid of a commercial kit
(A003-1-2) in keeping with the standard procedures of vendor. The level of superoxide dismutase (SOD) was tested at the wavelength of 450 nm by its appropriate commercial kit (A001-1-2) as instructed by the reagent manufacturer. The content of glutathione peroxidase (GSH-PX) was measured at 412 nm using its corresponding kit (A005-1-2) following the directions of vendor. All kits herein were obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China).

**TUNEL assay**

The evaluation of apoptosis among ARPE-19 cells was conducted by TUNEL assay. Briefly, ARPE-19 cells were fully dewaxed for 20 mins and hydrated. The sections were incubated with protease K for 30 mins to allow enzymes and antibodies to enter the cells. After rinsed with PBS for 3 times, TUNEL reagent (Gelatins, Shanghai, China) was carried out to detect DNA fragmentation at 37°C for 1 h. After that, the slices were subjected to incubation with DAPI for 2 min at room temperature. Finally, cells were washed with PBS for 5 times and observed under an Olympus CKX415SF5 fluorescent microscope (Poohor, Shanghai, China). The number of cells marked in green was counted [20].

**Western blotting assay**

Protein extracts were prepared from ARPE-19 cells and later lysed with RIPA buffer (Elabscience, Wuhan, China) on ice for obtaining total proteins. The same amounts of protein (20 µg) were isolated by 10% SDS-PAGE (Phygene, Fuzhou, China). The PVDF membranes were utilized to carry the isolated proteins and were later blocked with 5% skimmed milk. The incubation for these membranes was conducted with primary antibodies overnight at 4°C. Then, membranes were washed with PBS for three times and followed by a cultivation with HRP labeled secondary antibodies at room temperature. Finally, protein bands were observed using ECL luminescence reagent (Absin, Shanghai, China) and quantified by means of Image J software (National Institutes of Health, Maryland, USA) [21].

**Statistical analysis**

The data were recorded in the way of mean ± SD and analyzed employing SPSS software (version 20.0). The Shapiro–Wilk normality test is used to test the data normality distribution. Differences among multiple groups were analyzed using one-way ANOVA with a post hoc Bonferroni multiple-comparison test. The P value <0.05 was generated for the statistical significance.

**Results**

In the current study, we explored the role of CAR in DR. Functional assays revealed that CAR activated Nrf2/ARE pathway to inhibited HG-induced oxidative stress and apoptosis in retinal pigment epithelial cells, suggesting that CAR might be a novel strategy for treating DR.

**CAR increased the activities of ARPE-19 cells induced by HG**

To certify the impact of CAR on cell viability, we investigated the chemical structure of CAR and performed CCK-8 assay. As shown in Figure 1(a), the chemical structure of CAR was clearly presented. After that, we divided the experiment into five groups, the first four groups were added with 2.5, 5, 10, 20 µM CAR, respectively. Compared with the control group, no significant differences of cell viability were found in these three groups treated with 2.5, 5, 10 µM concentrations of CAR (Figure 1(b)). While in the group with CAR concentration of 20 µM, cell viability was significantly decreased (P < 0.05) (Figure 1(b)). Subsequently, 30 mM HG were added to the first four groups treated with CAR. Another group was added with only 30 mM HG. As seen from Figure 1(c), compared with the control group, cell viability in HG group was decreased sharply (P < 0.001). Cell viability in the three groups with 2.5, 5, and 10 µM CAR was increased in a concentration-dependent manner compared to HG group. However, when CAR concentration was 20 µM, cell viability was declined in comparison with the group with 10 µM CAR although it was elevated compared to HG group. Therefore, 2.5, 5, and 10 µM CAR were used for following
CAR increased the activities of ARPE-19 cells induced by HG. (a). The chemical structure formula of CAR was presented. (b). Detection of cell survival level after CAR treatment was conducted using CCK-8. (c). CCK-8 was in detection of the cell viability of ARPE-19 cells induced by HG after CAR treatment. Data are expressed as mean ± SD. *P < 0.05, **P < 0.001 versus control. †P < 0.05 versus HG.

experiments. Overall, the above data indicated that CAR exerted a facilitating effect on the cell viability induced by HG.

**CAR inhibited the inflammation and oxidative stress in HG-induced ARPE-19 cells**

To determine the function of CAR on inflammation and oxidative stress of HG-induced ARPE-19, levels of inflammatory cytokines and oxidative stress were measured. As demonstrated in Figure 2(a), there was a steep rise in the levels of the inflammatory cytokines including TNF-α, IL-6 and IL-1β in HG group as compared with the control group (P < 0.001). The levels of inflammatory cytokines showed a continuous downward trend in the groups with 2.5, 5, and 10 μM CAR (P < 0.001). In addition, it could be easily observed that oxidative stress markers SOD and GSH-PX levels were declined dramatically in HG group but steady rebound again in the groups with 2.5, 5, and 10 μM CAR (Figure 2(b), p < 0.001). While another marker MDA level exhibited an opposite trend to SOD and GSH-PX (P < 0.001). Given that results, we came to the conclusion that CAR inhibited the inflammation and oxidative stress in ARPE-19 cells induced by HG.

**CAR suppressed the apoptosis level in HG-induced ARPE-19 cells**

To find out whether CAR affected cell apoptosis, TUNEL assay and Western blot were carried out. There was a marked rise of the apoptotic capacity in the HG group but a continuous decline in a concentration-dependent manner in the groups with 2.5, 5, and 10 μM CAR (P < 0.001) (Figure 3(a,b)). Besides, compared with the control group, what could be clearly seen in Figure 3(c) was that the rapid decrease on Bcl-2 protein level in HG group gradually rose back up in the groups with addition of 2.5, 5, and 10 μM CAR (P < 0.05 and P < 0.001). In contrast to it, the levels of Bax, cleaved-caspase3, cleaved-caspase 9 were remarkably increased in HG group but decreased in the groups with addition of 2.5, 5, and 10 μM CAR (P < 0.05 and P < 0.001). Together, these
results provided important insights into the fact that CAR suppressed the apoptosis in HG-induced ARPE-19 cells.

**CAR activated Nrf2/ARE signaling pathway**

To confirm if CAR activated Nrf2/ARE signaling pathway, we employed Western blotting to test the levels of Nrf2/ARE signaling pathway-related proteins p-Nrf2, HO-1, and NQO-1. It was apparent from Figure 4 that the levels of p-Nrf2, HO-1, and NQO-1 in ARPE-19 cells were significantly inhibited by HG but promoted by 2.5, 5, 10 μM concentrations of CAR (P < 0.05, P < 0.01 and P < 0.001). To be summarized, CAR activated the Nrf2/ARE signaling pathway in HG-induced ARPE-19 cells.

**CAR inhibited the inflammation, oxidative stress and apoptosis in HG-induced ARPE-19 cells by activating Nrf2/ARE signaling pathway**

In this part, 10 μM CAR was selected for the next experiment. Meanwhile, 10 μmol/L Nrf2 inhibitor ML385 was added to validate that CAR exerted influence on cellular inflammation, oxidative stress and apoptosis in HG-induced ARPE-19 cells through modulating Nrf2/ARE signaling pathway. It can be seen from the data in Figure 5 (a) that the levels of the inflammatory cytokines TNF-α, IL-6 and IL-1β were rapidly elevated after adding ML385 (P < 0.001). From Figure 5(b), we can see that MDA level was increased while the levels of SOD and GSH-PX were sharply declined after the addition of ML385 (P < 0.01 and P < 0.001). At the same time, after CAR treatment, the addition of ML385 obviously promoted cell apoptosis in HG-induced ARPE-19 cells (P < 0.05 and P < 0.001) (Figure 5(c,d)). Moreover, as seen in Figure 5(e), compared with the HG+CAR group, the level of Bcl-2 was declined while Bax, cleaved-caspase 3, cleaved-caspase 9 were increased after adding ML385 (P < 0.05, P < 0.01 and P < 0.001). Taken together, CAR might inhibit the inflammation, oxidative stress and apoptosis of HG-induced ARPE-19 cells by activating Nrf2/ARE signaling pathway.

**Discussion**

Diabetic retinopathy (DR) is one of the most prevalent microvascular complications of diabetes and
a major cause of vision loss in the active age population. As mentioned earlier, the key points in the pathogenesis of this complication are oxidative stress and inflammation [22]. There are research reports that Procyanidin may protect RPE cells from high glucose-induced injury through the p53/mTOR autophagy pathway [23], Proanthocyanidins (PACs) can prevent retinal pigment epithelial cells from high glucose-induced injury via inhibiting the generation of ROS and activation of the NLRP3 inflammasome, suggesting PACs as a potential candidate for the management of DR [24]. CAR has been previously mentioned to ameliorate oxidative stress, inflammatory response, as well as cellular damage. This paper was designed to explore whether CAR had the potential to treat DR. For the reason that chronic and persistent hyperglycemia trigger early changes in DR, it eventually leads to vascular dysfunction [25]. We took advantage of this feature to establish a cellular model of DR under HG induction. Subsequently, different concentrations of CAR were added to observe the cellular changes. Overall, we found that CAR was able to enhance HG-induced ARPE-19 cell viability and inhibit cellular inflammation, oxidative stress and apoptosis. In addition, CAR was shown to activate the Nrf2/ARE signaling pathway. With the addition of the Nrf2 inhibitor ML385, the results suggested that CAR inhibited inflammation, oxidative stress and apoptosis in HG-induced ARPE-19 cells by activating the Nrf2/ARE signaling pathway.

CAR is a nonselective beta-blocker acting on β1-, β2-, and α1-adrenoceptors [26], has been
employed extensively in the treatment of chronic heart failure [27]. In addition, CAR is also available for the treatment of diabetic complications. For instance, CAR protects myocardium from injury by inhibiting myocardial inflammatory response, fibrosis, P66shc-mediated oxidative stress and myocardial apoptosis, suggesting that CAR may have potential for the treatment of diabetic cardiomyopathy [28]. Another example of this was the study carried out by Morsy who suggested that CAR protected rats from early diabetic nephropathy induced by streptozotocin, partially due to its antioxidant, anti-inflammatory activities and ability to alleviate podocyte damage [29]. Moreover, the promotive effect of CAR on cell viability has also been reported in numerous studies. For example, CAR effectively increases cell viability of renal cell [30]. Additionally, CAR significantly reduces H\textsubscript{2}O\textsubscript{2}-induced reactive oxygen species production, apoptosis, and combines with bone marrow mesenchymal stem cells to treat spinal cord injury by improving cell survival and oxidative stress microenvironment [31]. This study investigated CAR effect on ARPE-19 cells in DR. In our study, we found that CAR significantly improved the cell viability of AEPR19 cells induced by HG in a concentration-dependent manner, which was in line with previous studies. The difficulty of this study is that after we determined the dose of carvedilol by consulting the literature, we went through a large number of preliminary experiments to determine the time point for the drug to treat the cells. In addition, the time points at which CAR plays some roles are different at different times.

On the other hand, during the development of DR, pathologic angiogenesis is caused due to the secretion of cytokine-regulated pro-inflammatory mediators, such as TNF-α, IL-6 and IL-1β, as well as growth factors [25]. Many inflammatory cytokines are elevated in serum and ocular samples (vitreous and atrial fluid) in patients with diabetic DR [7]. At the same time, molecular pathways linked to inflammation, such as oxidative...
Figure 5. CAR inhibited the inflammation, oxidative stress and apoptosis in high-glucose-induced ARPE-19 cells by activating Nrf2/ARE signaling pathway. (a). After adding Nrf2 inhibitor ML385, the levels of inflammatory factors in cells were detected by ELISA kit. (b). Detection of oxidative stress levels was conducted in cells using corresponding kits. (C&D). TUNEL assay was utilized for apoptosis levels. (e). Detection of apoptosis-related protein expression levels Bcl-2, Bax, cleaved-caspase3 and cleaved-caspase9 in cells induced by HG was tested by Western blotting after CAR treatment. Data are expressed as mean ± SD. ***P < 0.001 versus control. **P < 0.01, ***P < 0.001 versus HG, ###P < 0.01, ####P < 0.001 versus HG + CAR.
stress, also changed [7]. In this study, it was clearly seen that the levels of TNF-α, IL-6 and IL-1β and the level of oxidative stress marker MDA were dramatically increased and the levels of SOD and GSH-PX in ARPE-19 cells were stimulated by HG, which meant that HG induced cellular inflammation and oxidative stress. Afterward, with the addition of CAR at different concentrations, we observed that the levels of inflammation cytokines TNF-α, IL-6 and IL-1β and MDA content were sharply reduced but the levels of SOD and GSH-PX were increased, which implied that CAR worked to suppress inflammation and oxidative stress in HG-induced ARPE-19 cells.

Furthermore, CAR plays an important role in apoptosis. A case in point is that CAR is capable of inhibiting apoptosis and ion channel remodeling in HL-1 cardiomyocytes expressing E334K cMyBPC [32]. CAR helps treat heart failure by inhibiting oxygen free radicals and apoptosis [33]. During our experiment, the result of TUNEL assay showed that the apoptosis level in ARPE-19 cells induced by HG was significantly suppressed by CAR. Besides, the protein levels of pro-apoptotic cytokines Bax, cleaved-caspase3 and cleaved-caspase9 were inhibited by CAR and the level of anti-apoptotic cytokines Bcl-2 was increased, which demonstrated that CAR truly offered an inhibitory effect on apoptosis.

Nrf2/ARE pathway plays a vital role in HG-induced neuronal damages [29]. Heme oxygenase-1 (HO-1) and NAD (P) H quinone oxidoreductase-1 (NQO-1) are two downstream factors of the Nrf2/ARE pathway [30]. A study notes that after myocardial I/R injury, Nrf2 level is down-regulated, the expressions of HO-1 and NQO1 located in the downstream of Nrf2 were reduced [31]. Additionally, CAR has been reported to activate the Nrf2/ARE pathway in a concentration-dependent manner [30]. According to our results in this study, we found that the levels of p-Nrf2, HO-1 and NQO-1 related to Nrf2/ARE pathway signaling were elevated in HG-induced ARPE-19 cells after addition of CAR, which suggested that CAR indeed posed a stimulative effect on the Nrf2/ARE pathway signaling.

ML385 is an inhibitor of Nrf2 and can attenuate the activation of Nrf2/HO-1 signaling [34]. Previously, we have shown that CAR can inhibit HG-induced inflammation, oxidative stress and apoptosis in ARPE-19 cells. And it activated the Nrf2/ARE pathway. Based on our observation, after adding the Nrf2 inhibitor ML385, we found that the levels of cellular inflammatory factors, oxidative stress and apoptosis were once again elevated, indicating that CAR could indeed activate the Nrf2/ARE signaling pathway to inhibit high-glucose-induced inflammation, oxidative stress and apoptosis in ARPE-19 cells.

Conclusion

To sum up, according to our studies performed in a cellular model of DR, the diabetic environment stimulates increased expression of inflammatory molecules, oxidative stress levels and apoptosis. CAR, an adrenergic receptor blocker with anti-inflammatory and anti-oxidative stress effects, effectively inhibited oxidative stress, apoptosis and cell damage in HG-induced retinal pigment epithelial cells by activating the Nrf2/ARE pathway, making it a promising future molecule for the treatment of DR. However, in addition to glucose stimulation, the pathway of inflammation production is also influenced by angiogenesis. Therefore, further studies on angiogenesis are still needed to better understand the exact molecular mechanisms of inflammation in DR patients.

Acknowledgements

Not available.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported there is no funding associated with the work featured in this article.

References

[1] Rodríguez ML, Perez S, Mena-Molla S, et al. Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: future Therapies. Oxid Med Cell Longev. 2019;2019: p. 4940825.
[2] Lois N, McCarter RV, O’Neill C, et al. Endothelial progenitor cells in diabetic retinopathy. Front Endocrinol (Lausanne). 2014;5: p. 44.

[3] Wang W, Lo ACY. Diabetic Retinopathy: pathophysiology and Treatments. Int J Mol Sci. 2018;19: p. 6.

[4] Simo-Servat O, Hernandez C, Simo R. Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Res. 2019;62(4): pp. 211–217.

[5] Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. 2017;139: pp. 7–14.

[6] Bucolo C, Marrazzo G, Platania CB, et al. Fortified extract of red berry, Ginkgo biloba, and white willow bark in experimental early diabetic retinopathy. J Diabetes. 2013;2013: p. 432695.

[7] Robison WG Jr., Kador PF, Kinoshita JH. Early retinal microangiopathy: prevention with aldose reductase inhibitors. Diabet Med. 1985;2(3): pp. 196–199.

[8] Arab HH, El-Sawalhi MM. Carvedilol alleviates adjuvant-induced arthritis and subcutaneous air pouch edema: modulation of oxidative stress and inflammatory mediators. Toxicol Appl Pharmacol. 2013;268(2): pp. 241–248.

[9] Wu Y, Li Z, Xiu AY, et al. Carvedilol attenuates carbon tetrachloride-induced liver fibrosis and hepatic sinusoidal capillarization in mice. Drug Des Devel Ther. 2019;13: p. 2667–2676.

[10] Amirshahrokhi K, Zohouri A. Carvedilol prevents pancreatic beta-cell damage and the development of type 1 diabetes in mice by the inhibition of proinflammatory cytokines, NF-kappaB, COX-2, iNOS and oxidative stress. Cytokine. 2021;138: p. 155394.

[11] Amirshahrokhi K, Khalili AR. Carvedilol attenuates paraplatin-induced lung injury by inhibition of proinflammatory cytokines, chemokine MCP-1, NF-kappaB activation and oxidative stress mediators. Cytokine. 2016;88: pp. 144–153.

[12] Liu B, Liu YJ. Carvedilol Promotes Retinal Ganglion Cell Survival Following Optic Nerve Injury via ASK1-p38 MAPK Pathway. CNS Neurol Disord Drug Targets. 2019;18(9): pp. 695–704.

[13] Buendia I, Michalska P, Navarro E, et al. Nrf2-ARE pathway: an emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. Pharmacol Ther. 2016;157: pp. 84–104.

[14] Bin J, Bai T, Zhao Q, et al. Parkin overexpression reduces inflammation-mediated cardiomyocyte apoptosis through activating Nrf2/ARE signaling pathway. J Recept Signal Transduct Res. 2020; pp. 1–6

[15] Wang L, Wang R, Jin M, et al. Carvedilol attenuates 6-hydroxydopamine-induced cell death in PC12 cells: involvement of Akt and Nrf2/ARE pathways. Neurochem Res. 2014;39(9): pp. 1733–1740.

[16] Maisto R, Oltra M, Vidal-Gil L, et al. ARPE-19-derived VEGF-containing exosomes promote neovascularization in HUVEC: the role of the melanocortin receptor 5. Cell cycle (Georgetown, Tex.). 2019;18(4): pp. 413–424

[17] Zhang QL, Yang JJ, Zhang HS. Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. Biomed Pharmacother Biomed Pharmacother. 2019;109: pp. 71–83.

[18] Zhang Q, Li HS, Li R, et al. Autophagy dysregulation mediates the damage of high glucose to retinal pigment epithelium cells. Int J Ophthalmol. 2021;14(6): pp. 805–811.

[19] Tong P, Peng QH, Gu LM, et al. LncRNA-MEG3 alleviates high glucose induced inflammation and apoptosis of retina epithelial cells via regulating miR-34a/SIRT1 axis. Exp Mol Pathol. 2019;107: pp. 102–109.

[20] Udawatte C, Qian H, Mangini NJ, et al. Taurine suppresses the spread of cell death in electrically coupled RPE cells. Molecular vision. 2008;14: pp. 1940–1950.

[21] Xiao H, Liu Z. Effects of microRNA-217 on high glucose-induced inflammation and apoptosis of human retinal pigment epithelial cells (ARPE-19) and its underlying mechanism. Mol Med Rep. 2019;20(6): pp. 5125–5133.

[22] Calderon GD, Juarez OH, Hernandez GE, et al. Oxidative stress and diabetic retinopathy: development and treatment. Eye (Lond). 2017;31(8): pp. 1122–1130.

[23] Li R, Li H, Zhang Q. Procyandin protects human retinal pigment epithelial cells from high glucose by inhibiting autophagy. Environmental toxicology. 2021;1–11.

[24] Li H, Li R, Wang L, et al. Proanthocyanidins attenuate the high glucose-induced damage of retinal pigment epithelial cells by attenuating oxidative stress and inhibiting activation of the NLRP3 inflammasome. J Biochem Mol Toxicol. 2021;35(9): p. e22845.

[25] Capitao M, Soares R. Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy. J Cell Biochem. 2016;117(11): pp. 2443–2453.

[26] Kheiri B, Abdalla A, Osman M, et al. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. Am J Cardiol. 2018;122(11): pp. 1959–1964.

[27] Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377): pp. 7–13.

[28] Zheng W, Li D, Gao X, et al. Carvedilol alleviates diabetic cardiomyopathy in diabetic rats. Exp Ther Med. 2019;17(1): pp. 479–487.

[29] Morsy MA, Ibrahim SA, Amin EF, et al. Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int. 2014;2014: p. 105214.
[30] Carvalho Rodrigues MA, Gobe G, Santos NA, et al. Carvedilol protects against apoptotic cell death induced by cisplatin in renal tubular epithelial cells. J Toxicol Environ Health A. 2012;75(16–17): pp. 981–990.

[31] Chen M, Chen S, Lin D. Carvedilol protects bone marrow stem cells against hydrogen peroxide-induced cell death via PI3K-AKT pathway. Biomed Pharmacother. 2016;78: pp. 257–263.

[32] Hu Y, Chen X, Li X, et al. MicroRNA1 downregulation induced by carvedilol protects cardiomyocytes against apoptosis by targeting heat shock protein 60. Mol Med Rep. 2019;19(5): pp. 3527–3536.

[33] Feuerstein G, Yue TL, Ma X, et al. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis. 1998;41(1 Suppl 1): pp. 17–24.

[34] Xie S, Deng W, Chen J, et al. Andrographolide Protects Against Adverse Cardiac Remodeling After Myocardial Infarction through Enhancing Nrf2 Signaling Pathway. Int J Biol Sci. 2020;16(1): pp. 12–26.